Stryker (NYSE:SYK) CAO William Berry Jr Sells 1,953 Shares

by · The Cerbat Gem

Stryker Corporation (NYSE:SYK – Get Free Report) CAO William Berry, Jr. sold 1,953 shares of Stryker stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the transaction, the chief accounting officer directly owned 2,833 shares in the company, valued at $1,035,433.17. The trade was a 40.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Stryker Trading Down 0.8%

NYSE:SYK traded down $2.77 on Monday, reaching $359.45. 2,009,019 shares of the stock traded hands, compared to its average volume of 1,446,221. The company’s 50 day moving average is $371.96 and its 200-day moving average is $381.27. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The firm has a market capitalization of $137.46 billion, a price-to-earnings ratio of 47.61, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Analyst Ratings Changes

SYK has been the topic of a number of recent analyst reports. UBS Group set a $408.00 price objective on Stryker in a research note on Monday, October 13th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $435.00 target price on shares of Stryker in a report on Friday. Needham & Company LLC restated a “buy” rating and set a $448.00 price target on shares of Stryker in a report on Friday. BTIG Research reaffirmed a “buy” rating and set a $410.00 price objective on shares of Stryker in a research report on Friday. Finally, Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Thirteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $434.37.

Read Our Latest Stock Analysis on Stryker

Institutional Trading of Stryker

Hedge funds have recently bought and sold shares of the business. Consolidated Portfolio Review Corp lifted its stake in shares of Stryker by 4.2% in the second quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after buying an additional 26 shares in the last quarter. Princeton Global Asset Management LLC raised its holdings in shares of Stryker by 16.9% in the 2nd quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock worth $71,000 after acquiring an additional 26 shares during the last quarter. Sunflower Bank N.A. lifted its position in Stryker by 4.0% in the 2nd quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after acquiring an additional 27 shares in the last quarter. Pitti Group Wealth Management LLC lifted its position in Stryker by 3.2% in the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after acquiring an additional 27 shares in the last quarter. Finally, Sachetta LLC boosted its stake in Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 27 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

(Get Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Further Reading